Treating Patients With Stage IV Lung Adenocarcinoma Without Actionable Oncogenic Drivers

In an interview with Targeted Oncology, Neeraj Agarwal, MD, discussed findings from the TITAN trial which were presented at ESMO 2023.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

Telisotuzumab vedotin demonstrated promising efficacy and safety in patients with advanced nonsquamous non–small cell lung cancer with high or intermediate c-Met expression.

In season 2, episode 1 of Targeted Talks, Nagashree Seetharamu, MD, led a conversation with Luis E. Raez, MD, about the evolving treatment landscape for EGFR exon 20–mutated lung cancer.

In an interview with Targeted Oncology, Jeff Stein, PhD, discussed the challenges and prospects of CD73-targeting agents.

In an interview with Targeted Oncology, Chris Haqq, MD, PhD, discussed the potential use of cancer vaccines in patients with KRAS-mutated pancreatic and colon cancer.